Australian Consumer Group Doubts Glucosamine Good For Arthritis
This article was originally published in PharmAsia News
A consumer group's review of glucosamine products sold in Australia found many lacked enough of the active ingredient to be effective in treating arthritis. The group Choice also said clinical trials so far have not proved glucosamine to be an effective treatment. The group said it studied 26 products containing the ingredient derived from crustacean shells and noted many trials on it have found placebos to be just as effective. Australian regulations set the amount of active ingredient per tablet or capsule. (Click here for more
You may also be interested in...
Concern and skepticism about Russia's rapid vaccine roll-out. Meanwhile Japan is latest to reach reaches deal with Pfizer/BioNTech.
Sun’s Q1 earnings were dented by provisions related to the generic pricing investigation settlement with the US Department of Justice of arm Taro, and the impact of pandemic-related lockdowns. Some clinic-administered products bore the brunt of lock-downs in parts of the US, though market share was unaffected.
Diabetes company Dexcom said it expects 2020 revenues to reach $1.85bn driven by new patient adoption of its continuous glucose monitoring (CGM) system including by people with type 2 diabetes. See what SVB Leerink analyst Danielle Antalffy said about Dexcom’s earnings results here.